Free Trial

Thermo Fisher Scientific (TMO) Stock Forecast & Price Target

Thermo Fisher Scientific logo
$408.92 +1.91 (+0.47%)
As of 12:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Thermo Fisher Scientific - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
4
Buy
17

Based on 21 Wall Street analysts who have issued ratings for Thermo Fisher Scientific in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 21 analysts, 4 have given a hold rating, and 17 have given a buy rating for TMO.

Consensus Price Target

$607.43
48.54% Upside
According to the 21 analysts' twelve-month price targets for Thermo Fisher Scientific, the average price target is $607.43. The highest price target for TMO is $686.00, while the lowest price target for TMO is $470.00. The average price target represents a forecasted upside of 48.54% from the current price of $408.93.
Get the Latest News and Ratings for TMO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Thermo Fisher Scientific and its competitors.

Sign Up

TMO Analyst Ratings Over Time

TypeCurrent Forecast
5/7/24 to 5/7/25
1 Month Ago
4/7/24 to 4/7/25
3 Months Ago
2/7/24 to 2/6/25
1 Year Ago
5/8/23 to 5/7/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
17 Buy rating(s)
18 Buy rating(s)
18 Buy rating(s)
12 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$607.43$653.23$656.86$607.35
Forecasted Upside48.54% Upside49.21% Upside14.89% Upside6.02% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

TMO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TMO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Thermo Fisher Scientific Stock vs. The Competition

TypeThermo Fisher ScientificMedical CompaniesS&P 500
Consensus Rating Score
2.81
2.82
2.54
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside49.11% Upside3,847.32% Upside18.95% Upside
News Sentiment Rating
Positive News

See Recent TMO News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/29/2025Argus
3 of 5 stars
David Toung
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$620.00 ➝ $470.00+10.27%
4/25/2025Scotiabank
5 of 5 stars
S. Nam
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetSector Perform ➝ Sector Perform$650.00 ➝ $605.00+42.68%
4/24/2025Royal Bank of Canada
3 of 5 stars
Conor McNamara
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$651.00 ➝ $637.00+51.31%
4/24/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Dan Leonard
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$715.00 ➝ $500.00+18.75%
4/24/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Daniel Arias
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$665.00 ➝ $620.00+46.59%
4/24/2025Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Vijay Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$585.00 ➝ $500.00+17.84%
4/24/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Brandon Couillard
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$580.00 ➝ $570.00+31.85%
4/24/2025Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Catherine Schulte
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$603.00 ➝ $573.00+32.54%
4/23/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Matthew Sykes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set TargetBuy ➝ Buy$610.00+41.10%
4/10/2025Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Luke Sergott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetEqual Weight ➝ Equal Weight$620.00 ➝ $475.00+11.86%
3/4/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Patrick Donnelly
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$650.00 ➝ $570.00+10.42%
2/3/2025Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Andrew Cooper
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$650.00 ➝ $667.00+11.46%
1/31/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Tejas Savant
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$647.00 ➝ $678.00+12.52%
1/10/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Burstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$630.00+15.60%
12/13/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$675.00 ➝ $660.00+26.05%
10/22/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$656.00 ➝ $686.00+16.92%
10/22/2024Bernstein Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform ➝ Market Perform$565.00 ➝ $625.00+6.30%
10/14/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Clark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$680.00+13.74%
10/1/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Johnson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$680.00+9.93%
9/20/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$650.00 ➝ $670.00+9.13%
6/3/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold ➝ Buy$600.00 ➝ $650.00+14.44%
4/30/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$660.00 ➝ $670.00+17.13%
4/25/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$600.00 ➝ $610.00+6.54%
12/13/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$575.00+15.58%
10/26/2023KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Sector Weight
7/13/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Outperform$620.00+17.89%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 12:15 PM ET.


Should I Buy Thermo Fisher Scientific Stock? TMO Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, May 6, 2025. Please send any questions or comments about these Thermo Fisher Scientific pros and cons to contact@marketbeat.com.

Thermo Fisher Scientific
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Thermo Fisher Scientific Inc.:

  • The current stock price is around $585.59, reflecting a strong market position and investor confidence in the company's growth potential.
  • Recent insider trading activity indicates confidence in the company's future, with executives maintaining significant ownership despite recent sales.
  • Thermo Fisher Scientific Inc. has a diverse portfolio, providing life sciences solutions and analytical instruments, which positions it well in various growing markets.
  • The company has demonstrated robust financial performance, with recent insider sales totaling over $13 million, suggesting liquidity and strong cash flow.
  • With only 0.33% of the stock owned by insiders, there is potential for increased market participation, which could drive stock prices higher.

Thermo Fisher Scientific
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Thermo Fisher Scientific Inc. for these reasons:

  • Recent insider sales, while indicating liquidity, also represent a decrease in ownership, which could signal a lack of confidence in short-term performance.
  • The stock has experienced fluctuations, and the recent average sale price of $585.59 may not reflect long-term growth potential.
  • With a significant portion of recent sales attributed to executives, there may be concerns about the company's immediate outlook and strategic direction.
  • Market conditions can be volatile, and the life sciences sector may face challenges that could impact Thermo Fisher Scientific Inc.'s performance.
  • Investors should consider the competitive landscape, as advancements by competitors in life sciences solutions could affect market share and profitability.

TMO Forecast - Frequently Asked Questions

According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Thermo Fisher Scientific is $607.43, with a high forecast of $686.00 and a low forecast of $470.00.

21 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Thermo Fisher Scientific in the last year. There are currently 4 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TMO shares.

According to analysts, Thermo Fisher Scientific's stock has a predicted upside of 48.54% based on their 12-month stock forecasts.

Thermo Fisher Scientific has been rated by research analysts at Argus, Barclays, Citigroup, Evercore ISI, Robert W. Baird, Royal Bank of Canada, Scotiabank, Stifel Nicolaus, The Goldman Sachs Group, UBS Group, and Wells Fargo & Company in the past 90 days.

Analysts like Thermo Fisher Scientific less than other "medical" companies. The consensus rating score for Thermo Fisher Scientific is 2.81 while the average consensus rating score for "medical" companies is 2.82. Learn more on how TMO compares to other companies.


This page (NYSE:TMO) was last updated on 5/7/2025 by MarketBeat.com Staff
From Our Partners